본문 바로가기 주메뉴 바로가기

ABOUT US

WHO WE ARE

Who we are

The most effective treatment for devastating human diseases such as cancer or autoimmune disease is an innovative cell/gene therapy based upon creative idea and scrupulous understanding of human immune system.

Through close collaboration network with international partners and securement of healthcare infrastructure for systematic medical service as well as production of GMP material, BiGEN will exert its best efforts to achieve the goal of providing meaningful therapeutic benefits for patients suffering from diseases for which treatment is currently limited.

We will be pleased to see the smile of patients who have recovered their health via innovative cell/gene therapy, which definitely drives us to strive to achieve our goal.

Corporate profile

Company Name BiGEN Co., Ltd.
CEO Mr. Myoung Ho Jeong
Establishment February 24, 2015
Capital 10 billion KRW
Head Office 684, 1193, Jungang-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10414, Republic of Korea
Gangnam Office 7F, Gangnam 358Tower, 358, Gangnam-daero, Gangnam-gu, Seoul, 06241, Republic of Korea

Board members

Directors
Myoung Ho Jeong (C.E.O / Chairman of BoD)
Sunjin Oh (Vice President / BoD)
Gyung Chul Kim (Lawyer / BoD)
Auditor Jun Hong Min (Professor of Chung-Ang Univ.)

History